Want to see PRE full AI Analyst Report?
PRE Stock Chart & Stats
$23.25
-$0.68(-3.50%)
At close: 4:00 PM EDT
$23.25
-$0.68(-3.50%)
Day’s Range― - ―
52-Week Range$11.37 - $27.24
Previous Close$18.74
Volume149.20K
Average Volume (3M)260.84K
Market Cap
$393.79M
Enterprise Value$221.33
Total Cash (Recent Filing)$109.39M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Nov 05, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend Yield2.46%
Share Statistics
EPS (TTM)-4.16
Shares Outstanding15,562,491
10 Day Avg. Volume198,339
30 Day Avg. Volume260,838
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.00Price Target Upside59.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.46
Revenue Forecast (FY)$223.85M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Raised GuidanceSharp revenue acceleration, higher forward guidance, and a growing annualized run rate indicate strong customer adoption and expanding commercial scale. If execution continues, this growth can improve operating leverage, strengthen Prenetics’ market position, and support investment in its consumer health platform.
Recurring Subscribers And Improving Customer EconomicsA high recurring-revenue mix and expanding subscriber base provide greater revenue visibility than one-time testing or product purchases alone. Improving customer acquisition costs and reported gross-profit returns suggest the platform may scale efficiently, supporting more durable economics as cohorts mature.
Improving Margins And Operating LeverageHigher gross and contribution margins show that incremental revenue is becoming more economically valuable, while lower fixed costs indicate emerging operating leverage. This combination can help narrow losses over time and improve the company’s ability to convert growth into sustainable profitability.
Bears Say
Persistent Losses And Negative Cash GenerationPrenetics continues to consume cash while funding growth, and large operating losses mean revenue expansion has not yet translated into sustainable profitability. Continued burn could constrain reinvestment, increase reliance on financing, and leave the business exposed if growth or margin improvement slows.
Dependence On External Growth FinancingThe growth strategy relies materially on external funding to sustain customer acquisition, making future expansion dependent on financing availability and cohort performance. Repayment obligations tied to customer collections could also reduce future cash flexibility and increase financial pressure if returns weaken.
Immature Cohorts And Unproven Clinical DifferentiationReported acquisition returns and retention metrics may change as younger customer cohorts mature, so current unit economics are not fully proven across the customer lifecycle. Pending clinical results also mean the company’s science-based differentiation remains prospective rather than established.
Prenetics Group News
PRE FAQ
What was Prenetics Group’s price range in the past 12 months?
Prenetics Group lowest stock price was $11.37 and its highest was $27.24 in the past 12 months.
What is Prenetics Group’s market cap?
Prenetics Group’s market cap is $393.79M.
When is Prenetics Group’s upcoming earnings report date?
Prenetics Group’s upcoming earnings report date is Nov 05, 2026 which is in 36 days.
How were Prenetics Group’s earnings last quarter?
Prenetics Group released its earnings results on Aug 18, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.84 by $0.31.
Is Prenetics Group overvalued?
According to Wall Street analysts Prenetics Group’s price is currently Undervalued.
Does Prenetics Group pay dividends?
Prenetics Group pays a Quarterly dividend of $0.7 which represents an annual dividend yield of 2.46%. See more information on Prenetics Group dividends here
What is Prenetics Group’s EPS estimate?
Prenetics Group’s EPS estimate is -0.83.
How many shares outstanding does Prenetics Group have?
Prenetics Group has 15,562,491 shares outstanding.
What happened to Prenetics Group’s price movement after its last earnings report?
Prenetics Group reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.84. Following the earnings report the stock price went up 0.155%.
Which hedge fund is a major shareholder of Prenetics Group?
Currently, no hedge funds are holding shares in PRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prenetics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (59.14% Upside)
$37.00 (59.14% Upside)
Blogger Sentiment
Bullish
PRE Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth $999.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.83%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prenetics Group
Prenetics Global Limited is a consumer health sciences company that has pivoted to focus on a consumer health and longevity platform. The company's main brand is IM8, which offers science-backed nutritional supplements. It also operates CircleDNA, a consumer genetic testing brand that provides personalized health reports based on sequencing technology.
PRE Company Deck
PRE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong growth story with multiple concrete operational and commercial milestones: record revenues, dramatic customer growth, improving unit economics, raised guidance, a $1B financing commitment, and ongoing clinical trials that enhance credibility. The primary negatives are high near-term marketing-driven losses, dependence on financing to fund customer acquisition, and the relative youth of cohorts and trials (outcomes pending). On balance, the material upward momentum, improving metrics (CAC, margins, contribution profit), and secured funding outweigh the current losses and risks.View all PRE earnings summariesPRE Stock 12 Month Forecast
Average Price Target
$37.00
▲(59.14% Upside)
Technical Analysis
Ownership Overview
5.22% Insiders
0.04% Mutual Funds
2.71% Other Institutional Investors
91.96% Public Companies and
Individual Investors